As we frequently report here on the blog, there has been increasing activity in BPCIA litigation concerning a variety of proposed and marketed biosimilar products. The coming year is likely to bring even more activity, with three cases scheduled for trial, several others in discovery or appeal, and new complaints likely. For a primer on what to expect in 2018, check out this article published last month by BioPharmaDIVE and written by Goodwin attorneys and BMW editors Joshua Whitehill and Alison Siedor.
The post Article Regarding The 2018 Biosimilar Litigation Landscape by BMW Editors appeared first on Goodwin Procter BioSimilars Blog.